FDA Approves BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA announced the approval of the generic version of Bisoprolol Fumarate and Hydrochlorothiazide (NDA020186), a broad-spectrum hypertension treatment originally launched in 1993. The availability of this FDA-approved generic is anticipated to significantly intensify competitive pricing in the high-demand antihypertensive market, driving revenue growth for Teva through volume-based gains.